Bakul Patel, MD
Neurology · Cincinnati, OHNPI 1295881894
Payments from drug & device makers
Across 1,269 payments — averaging $37.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Biohaven Pharmaceuticals, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Livanova USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- MDD US Operations, LLC$1K
- plus $14K from 51 others
What the payments were for
- Speaking & faculty fees$23,99651%
- Travel & lodging$1,7454%
- Food & beverage$20,95544%
- Education$5281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$22,894
- NURTEC ODT$2,000
- VNS Therapy$1,364
- GOCOVRI$286
- INGREZZA$242
- VRAYLAR$240
- Austedo XR$234
- AIMOVIG$225
- WATCHMAN Access System$145
- WAINUA$126
- AJOVY$125
- CREXONT$125
- UPLIZNA$124
- Leqembi$123
- VYVGART$121
- Rystiggo$120
- Auvelity$118
- TARPEYO$116
- XCOPRI$115
- SUNOSI$112
How this compares
$47,224 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $240,708 |
| Nurtec OdtRimegepant Sulfate | 131 | $133,734 |
| Austedo XrDeutetrabenazine | 16 | $120,967 |
| QuliptaAtogepant | 77 | $86,425 |
| NourianzIstradefylline | 23 | $84,728 |
| UbrelvyUbrogepant | 55 | $79,193 |
| Aimovig AutoinjectorErenumab-Aooe | 79 | $67,964 |
| NuplazidPimavanserin Tartrate | 13 | $65,783 |
| RexultiBrexpiprazole | 40 | $60,200 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 53 | $38,542 |
| BriviactBrivaracetam | 20 | $28,885 |
| GocovriAmantadine Hcl | 13 | $27,007 |
| Emgality PenGalcanezumab-Gnlm | 24 | $23,194 |
| RytaryCarbidopa/Levodopa | 15 | $19,608 |
| OngentysOpicapone | 15 | $14,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,381 | $255,05444 claims |
| AbbVieQulipta, Ubrelvy | $25,934 | $165,618132 claims |
| PfizerNurtec Odt | $877 | $133,734131 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,495 | $120,96716 claims |
| Kyowa Kirin, Inc.Nourianz | $144 | $84,72823 claims |
| Acadia Pharmaceuticals IncNuplazid | $484 | $65,78313 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $820 | $60,20040 claims |
| UCB, Inc.Briviact | $876 | $28,88520 claims |
| MDD US Operations, LLCGocovri | $1,155 | $27,00713 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $838 | $20,47826 claims |
| Upsher-smith Laboratories LLCTopiramate | $47 | $84076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.
Other neurology in Cincinnati
- Aram ZabetiCincinnati$5.3M
- Hani KushlafCincinnati$1.9M
- Alberto EspayCincinnati$785K
- Brandon ForemanCincinnati$677K
- Andrew DukerCincinnati$620K
- Michelle BowmanCincinnati$419K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.